European Pharmaceutical Review
MARCH 9, 2023
1 These substances “are pharmacologically and biologically active at low doses,” Dr Kishore Hotha, Global Head of Analytical Research & Development at Veranova, explained. ” Highly potent APIs are pharmacologically and biologically active compounds at low doses. What training is required for employees to handle HPAPIs safely?
pharmaphorum
JANUARY 17, 2023
The AMP technology was developed by the laboratories of Darrell Irvine, professor of biomedical engineering in the Koch Institute of Integrative Cancer Research at MIT, who is a co-founder of Elicio, as well as serving as a consultant to the company and head of its scientific advisory board. . Darrell Irvine.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Medgadget
NOVEMBER 24, 2022
The basis for many pharmacological interactions between drugs and cells, and indeed many physiological or pathological interactions involving biological signaling molecules, involves a molecule, termed a ligand, binding to a receptor that is typically present on the cell membrane.
Pharmaceutical Technology
APRIL 25, 2023
sCFH is an engineered and improved version of complement factor H (CFH) that can fit into adeno-associated virus (AAV) vectors with solid expression and applications confirmed in cultured human cells in vitro, in addition to various preclinical animal models in vivo. The firm will also receive single-digit royalties on net sales.
Evolve Your Success
OCTOBER 24, 2023
We would typically engage with Stryker’s engineering, product management, product development, marketing, or even their R&D teams. A re they engineers ? One is an engineer who came into sales. I was using all I knew about biology, physiology, and pharmacology. H ow does that work? They decide to create a device.
European Pharmaceutical Review
OCTOBER 27, 2022
The report identifies access to talented R&D and CMC personal as the main potential headwinds to market growth – particularly for cell and gene therapy innovators – and predicts an ongoing cooling of China’s bio innovation engine.
European Pharmaceutical Review
DECEMBER 11, 2023
Based on learnings from ASOs and siRNAs they also leverage unique engineering and drug delivery techniques that enable them to target a broader set of cell types, including many that have been previously untreatable with RNA therapeutics. Brain pharmacology of intrathecal antisense oligonucleotides revealed through multimodal imaging.
Expert insights. Personalized for you.
98 
Let's personalize your content